Latest filings (excl ownership)
6-K
Sales growth of 6.7% at CER and business EPS(1) of €1.78
25 Apr 24
F-3ASR
Automatic shelf registration (foreign)
4 Apr 24
S-8
Registration of securities for employees
4 Apr 24
6-K
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
20 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 24
6-K
Current report (foreign)
27 Feb 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
2 Feb 24
6-K
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
1 Feb 24
6-K
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
23 Jan 24
6-K
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
17 Jan 24
6-K
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
27 Dec 23
6-K
Current report (foreign)
20 Dec 23
F-6EF
Automatic registration for ADRs (foreign)
18 Dec 23
6-K
Current report (foreign)
1 Dec 23
6-K
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
27 Oct 23
6-K
Sanofi Enters Next Chapter of Play to Win Strategy
27 Oct 23
6-K
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
26 Oct 23
6-K
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
20 Oct 23
6-K
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
11 Oct 23
6-K
Current report (foreign)
27 Sep 23
6-K
Sanofi announces changes to its Executive Committee
5 Sep 23
6-K
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
10 Aug 23
6-K
Solid Q2 performance and strong pipeline momentum
28 Jul 23
6-K
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
28 Jul 23
6-K
Condensed Half-year Consolidated Financial Statements
28 Jul 23
6-K
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
24 Jul 23
6-K
Current report (foreign)
5 Jul 23
6-K
Current report (foreign)
20 Jun 23
6-K
Approval of the financial statements for the fiscal year 2022
2 Jun 23
SD
Conflict minerals disclosure
30 May 23
6-K
Current report (foreign)
23 May 23
6-K
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
27 Apr 23
6-K
Current report (foreign)
27 Apr 23
SC TO-T/A
Third party tender offer statement (amended)
27 Apr 23
SC TO-T/A
Third party tender offer statement (amended)
26 Apr 23
6-K
Current report (foreign)
24 Apr 23
6-K
Current report (foreign)
11 Apr 23
SC TO-T/A
Third party tender offer statement (amended)
10 Apr 23
Latest ownership filings
SC 13G/A
Amundi
14 Feb 24
SC 13G/A
DODGE & COX
13 Feb 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G
MeiraGTx Holdings plc
6 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
DODGE & COX
14 Feb 23
SC 13G/A
Amundi
10 Feb 23
SC 13G/A
BlackRock Inc.
7 Feb 23
11-K
Annual report of employee stock purchases
29 Jun 22
11-K
Annual report of employee stock purchases
29 Jun 22
SC 13G/A
Amundi
22 Feb 22
SC 13G/A
Amundi
15 Feb 22
SC 13G
DODGE & COX
14 Feb 22
SC 13G
Icosavax, Inc.
8 Feb 22
SC 13G/A
BlackRock Inc.
3 Feb 22
4
Translate Bio, Inc.
14 Sep 21
3
Translate Bio, Inc.
12 Aug 21
SC 13D
Translate Bio, Inc.
12 Aug 21
4
Icosavax, Inc.
2 Aug 21
3
Icosavax, Inc.
28 Jul 21
11-K
Annual report of employee stock purchases
29 Jun 21
11-K
Annual report of employee stock purchases
29 Jun 21
SC 13G
LAVA Therapeutics NV
31 Mar 21
SC 13G
Amundi
16 Feb 21
SC 13G
Revolution Medicines, Inc.
11 Feb 21
SC 13G
Translate Bio, Inc.
4 Feb 21
SC 13G/A
BlackRock Inc.
1 Feb 21
4
Inozyme Pharma, Inc.
29 Jul 20
3
Inozyme Pharma, Inc.
23 Jul 20
11-K
Annual report of employee stock purchases
26 Jun 20
11-K
Annual report of employee stock purchases
26 Jun 20
SC 13D/A
REGENERON PHARMACEUTICALS, INC.
17 Jun 20
4
REGENERON PHARMACEUTICALS, INC.
11 Jun 20
4
REGENERON PHARMACEUTICALS, INC.
29 May 20
SC 13D/A
REGENERON PHARMACEUTICALS, INC.
29 May 20
4
REGENERON PHARMACEUTICALS, INC.
11 Mar 20
SC 13G/A
Unum Therapeutics Inc.
10 Feb 20
SC 13G/A
Regulus Therapeutics Inc.
10 Feb 20
SC 13G/A
Beneficial ownership report (amended)
10 Feb 20